[{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"e26feb64-5ce0-4689-b638-098d6bd0300f","acronym":"E-VIRTUE","url":"https://clinicaltrials.gov/study/NCT06041503","created_at":"2025-02-25T12:29:47.446Z","updated_at":"2025-02-25T12:29:47.446Z","phase":"Phase 2","brief_title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","source_id_and_acronym":"NCT06041503 - E-VIRTUE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"5416351c-6e6b-41af-9e81-7fd2a0e36c13","acronym":"GETUG 13","url":"https://clinicaltrials.gov/study/NCT00104676","created_at":"2021-01-18T00:20:19.559Z","updated_at":"2025-02-25T16:35:55.671Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","source_id_and_acronym":"NCT00104676 - GETUG 13","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 11/26/2003","start_date":" 11/26/2003","primary_txt":" Primary completion: 03/29/2012","primary_completion_date":" 03/29/2012","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2025-02-06"},{"id":"62adebca-4b95-438d-afa0-1e8661c4fb8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262530","created_at":"2022-03-02T16:52:30.929Z","updated_at":"2025-02-25T16:26:48.535Z","phase":"Phase 1/2","brief_title":"Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors","source_id_and_acronym":"NCT05262530","lead_sponsor":"BioNTech SE","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT142"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-31"},{"id":"0d376833-0db0-4c3f-a481-a0fdb012621c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04449549","created_at":"2021-01-18T21:24:29.334Z","updated_at":"2024-07-02T16:34:25.844Z","phase":"Phase 2","brief_title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","source_id_and_acronym":"NCT04449549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2024-06-14"},{"id":"118a4b55-36eb-4902-b388-cfb891dcf143","acronym":"","url":"https://clinicaltrials.gov/study/NCT04113122","created_at":"2021-01-18T20:06:31.712Z","updated_at":"2024-07-02T16:35:05.931Z","phase":"","brief_title":"Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study","source_id_and_acronym":"NCT04113122","lead_sponsor":"University Medical Center Groningen","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 02/09/2019","start_date":" 02/09/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"96e07c94-7a83-4ec3-b148-9faedc5d7126","acronym":"HFB-200301-01","url":"https://clinicaltrials.gov/study/NCT05238883","created_at":"2022-02-14T15:52:46.465Z","updated_at":"2024-07-02T16:35:06.647Z","phase":"Phase 1","brief_title":"A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05238883 - HFB-200301-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • emunkitug (HFB200301)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"a9d4e6d4-5f22-4193-a580-814e593b3884","acronym":"","url":"https://clinicaltrials.gov/study/NCT06389409","created_at":"2024-04-29T16:49:33.496Z","updated_at":"2024-07-02T16:35:07.133Z","phase":"","brief_title":"Study on the Quality of Life and Functional/Oncological Outcome of Testicular Cancer Patients","source_id_and_acronym":"NCT06389409","lead_sponsor":"IRCCS San Raffaele","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"],"overall_status":"Recruiting","enrollment":" Enrollment 3000","initiation":"Initiation: 08/24/2010","start_date":" 08/24/2010","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 08/31/2040","study_completion_date":" 08/31/2040","last_update_posted":"2024-04-29"},{"id":"dc3869b4-fd2e-4860-99c7-096db7913cb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836688","created_at":"2023-05-01T14:03:54.344Z","updated_at":"2024-07-02T16:35:11.661Z","phase":"","brief_title":"A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors","source_id_and_acronym":"NCT05836688","lead_sponsor":"University of California, Irvine","biomarkers":" IL6 • TNFA • IL1R1 • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1R1 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-04-03"},{"id":"2e1082a5-a1f6-4914-a8d9-c58f5de1c0cb","acronym":"SEMS","url":"https://clinicaltrials.gov/study/NCT02537548","created_at":"2021-01-18T12:16:28.563Z","updated_at":"2024-07-02T16:35:14.218Z","phase":"","brief_title":"Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma","source_id_and_acronym":"NCT02537548 - SEMS","lead_sponsor":"University of Southern California","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 08/28/2015","start_date":" 08/28/2015","primary_txt":" Primary completion: 08/28/2025","primary_completion_date":" 08/28/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2024-03-18"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"45ddfe43-42e0-4c84-8b8f-33717442454d","acronym":"CHANCE","url":"https://clinicaltrials.gov/study/NCT03976518","created_at":"2021-01-18T19:33:28.409Z","updated_at":"2024-07-02T16:35:16.865Z","phase":"Phase 2","brief_title":"Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)","source_id_and_acronym":"NCT03976518 - CHANCE","lead_sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-03-01"},{"id":"53124618-2267-481b-8fe0-bf52fc60b679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00936936","created_at":"2021-01-18T03:38:02.528Z","updated_at":"2024-07-02T16:35:20.708Z","phase":"Phase 2","brief_title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","source_id_and_acronym":"NCT00936936","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • ifosfamide • etoposide IV • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 06/02/2009","start_date":" 06/02/2009","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-06"},{"id":"d92c9e11-bf8f-4526-95a3-ebcab2c24614","acronym":"","url":"https://clinicaltrials.gov/study/NCT05317078","created_at":"2022-04-07T12:57:14.157Z","updated_at":"2024-07-02T16:35:23.817Z","phase":"Phase 1","brief_title":"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications","source_id_and_acronym":"NCT05317078","lead_sponsor":"Amgen","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 expression","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 794"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 08/10/2026","primary_completion_date":" 08/10/2026","study_txt":" Completion: 02/23/2028","study_completion_date":" 02/23/2028","last_update_posted":"2024-01-11"},{"id":"9a153527-03e4-4f0e-a267-102de598735a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410717","created_at":"2022-06-08T11:58:15.716Z","updated_at":"2024-07-02T16:35:24.094Z","phase":"Phase 1","brief_title":"CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors","source_id_and_acronym":"NCT05410717","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" AXL • MSLN • CLDN6 • GPC3","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AXL • MSLN • CLDN6 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6-CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/31/2034","study_completion_date":" 05/31/2034","last_update_posted":"2024-01-09"},{"id":"fc3bebd3-4c0e-45cc-a032-11c1ad881bfb","acronym":"SWOG-S1823","url":"https://clinicaltrials.gov/study/NCT04435756","created_at":"2021-01-18T21:21:24.405Z","updated_at":"2024-07-02T16:35:26.523Z","phase":"","brief_title":"A Study of miRNA 371 in Patients With Germ Cell Tumors","source_id_and_acronym":"NCT04435756 - SWOG-S1823","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 956","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-12-12"},{"id":"aa8467ad-c072-4b95-8f7a-4e50666ebdc6","acronym":"FAPI PET RDRC","url":"https://clinicaltrials.gov/study/NCT04459273","created_at":"2023-10-21T07:12:20.148Z","updated_at":"2024-07-02T16:35:33.555Z","phase":"Phase 1","brief_title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","source_id_and_acronym":"NCT04459273 - FAPI PET RDRC","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-13"},{"id":"a20ca03c-e4c8-424b-9577-602d1900d998","acronym":"SWENOTECA-ABC","url":"https://clinicaltrials.gov/study/NCT02341989","created_at":"2021-01-18T11:07:54.417Z","updated_at":"2024-07-02T16:35:43.889Z","phase":"Phase 3","brief_title":"Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer","source_id_and_acronym":"NCT02341989 - SWENOTECA-ABC","lead_sponsor":"St. Olavs Hospital","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • etoposide IV • bleomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/01/2035","primary_completion_date":" 12/01/2035","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2023-07-06"},{"id":"f263e4c7-8d97-4e67-989f-b832aa084e2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01873326","created_at":"2021-01-18T08:23:43.317Z","updated_at":"2024-07-02T16:35:44.198Z","phase":"Phase 2","brief_title":"Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","source_id_and_acronym":"NCT01873326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AFP","pipe":" | ","alterations":" LDH elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • etoposide IV • bleomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-30"},{"id":"1f49581a-ccdf-45d6-b014-9fa49967e11d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499291","created_at":"2021-01-18T01:47:16.522Z","updated_at":"2024-07-02T16:35:47.102Z","phase":"","brief_title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT00499291","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CYP2C8","pipe":"","alterations":" ","tags":["CYP2C8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-05-25"},{"id":"c18a797f-f388-457a-8936-39bcb7181e0b","acronym":"MyBrain","url":"https://clinicaltrials.gov/study/NCT05840575","created_at":"2023-05-03T15:04:43.419Z","updated_at":"2024-07-02T16:35:49.160Z","phase":"","brief_title":"Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","source_id_and_acronym":"NCT05840575 - MyBrain","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-05-02"},{"id":"51df4c7e-9525-47ee-b2c1-7e920a7c1596","acronym":"OTST","url":"https://clinicaltrials.gov/study/NCT01970696","created_at":"2021-01-18T08:57:53.404Z","updated_at":"2024-07-02T16:35:52.852Z","phase":"","brief_title":"International Ovarian \u0026 Testicular Stromal Tumor Registry","source_id_and_acronym":"NCT01970696 - OTST","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/08/2011","start_date":" 12/08/2011","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2023-03-21"},{"id":"7d0ad35c-729c-4a9a-9c46-630300efb330","acronym":"","url":"https://clinicaltrials.gov/study/NCT00053352","created_at":"2021-01-18T00:06:05.785Z","updated_at":"2024-07-02T16:36:28.005Z","phase":"Phase 3","brief_title":"Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors","source_id_and_acronym":"NCT00053352","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 302","initiation":"Initiation: 11/03/2003","start_date":" 11/03/2003","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2021-07-13"}]